Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPA Regimen for Conversion Therapy in ELM Gastric Cancer
NCT03258034Phase 2Unknown
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Aug 2017
- Primary completion
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Rivoceranib in gastric cancer (GC), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Status: unknown.
02
Drugs
Rivoceranib
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT03258034.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03258034.